With GLP-1s to treat the condition not specifically approved by the TGA, patients are being prescribed them off-label
-
Get our breaking news email, free app or daily news podcast
Women living with a chronic hormonal condition should have access to taxpayer-funded weight loss medications, advocates say.
The Polyendrocrine Metabolic Ovarian Syndrome Association of Australia (POSAA) is urging for GLP-1 drugs to be approved on the Pharmaceutical Benefits Scheme for people living with the condition.
The post Women with PMOS should get subsidised weight loss drugs, advocates say appeared first on World news | The Guardian.
